Latest revenue
$781.5M
as of 2026-03-31
Latest net income
$274.9M
as of 2026-03-31
Net margin
35.2%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think UTHR is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $23.32B
- Enterprise value
- $22.04B
- P/E (trailing)
- 17.5×
- Forward P/E
- —
- P/B
- 3.95×
- Dividend yield
- 0.0%
- 52-wk high
- $609.35
- 52-wk low
- $272.12
- Beta
- —
- Shares out
- 42.4M
5-year trend
What this company does
Item 1. Business Overview Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies. As a public benefit corporation (PBC), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders. Our public benefit purpose, as outlined in our charter and approved by our…
AI summary unavailable — showing raw filing excerpt
Generated from UTHR's filing dated 2026-02-25
Key risks
Item 1A. Risk Factors Investing in our securities involves uncertainty and risk due to a variety of factors. You should carefully consider each of the following risks and all of the other information contained in this Report and in other documents that we file with, or furnish to, the SEC before making any investment decision with respect to our securities. Statements in this section are based on our beliefs and opinions regarding matters that could materially adversely affect us in the future and are not representations as to whether such matters have or have not occurred previously. Further, the risks and uncertainties described below are not the only ones we face and should not be…
AI summary unavailable — showing raw filing excerpt
Generated from UTHR's filing dated 2026-02-25
Profitability
Operating margin
46.9%
2.0%Net margin
41.9%
1.0%Return on equity
18.8%
1.4%Return on assets
16.9%
4.4%Leverage
Debt / equity
0.11×
22.6%Long-term debt / equity
0.00×
100.0%Debt / assets
9.9%
20.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $781.5M | -1.6% | $274.9M | -14.7% | 35.2% |
Q4 2025 2025-12-31 | $790.2M | +7.4% | $364.3M | +20.9% | 46.1% |
Q3 2025 2025-09-30 | $799.5M | +6.8% | $338.7M | +9.6% | 42.4% |
Q2 2025 2025-06-30 | $798.6M | +11.7% | $309.5M | +11.3% | 38.8% |
Q1 2025 2025-03-31 | $794.4M | +17.2% | $322.2M | +5.1% | 40.6% |
Q4 2024 2024-12-31 | $735.9M | — | $301.3M | — | 40.9% |
Q3 2024 2024-09-30 | $748.9M | +22.9% | $309.1M | +15.5% | 41.3% |
Q2 2024 2024-06-30 | $714.9M | +19.8% | $278.1M | +7.3% | 38.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on UTHR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$863.9K
Insider selling
$462.0M
Net activity
−$461.2M
Distinct insiders
10
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns UTHR
Institutional value
$11.51B
Total shares held
20.6M
Distinct holders
562
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.4M | $3.20B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | $1.19B | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $1.16B | — | New |
| 4 | ASSETMARK, INC | 616.0K | $365.3M | — | New |
| 5 | Invesco Ltd. | 608.4K | $360.7M | — | New |
| 6 | DIMENSIONAL FUND ADVISORS LP | 512.7K | $304.0M | — | New |
| 7 | BAILLIE GIFFORD & CO | 428.1K | $253.9M | — | New |
| 8 | Bank of New York Mellon Corp | 329.1K | $195.2M | — | New |
| 9 | Swedbank AB | 327.1K | $194.0M | — | New |
| 10 | Pictet Asset Management Holding SA | 309.2K | $183.3M | — | New |
| 11 | JPMORGAN CHASE & CO | 291.6K | $171.6M | — | New |
| 12 | FRANKLIN RESOURCES INC | 278.0K | $164.8M | — | New |
| 13 | FIRST TRUST ADVISORS LP | 270.6K | $160.4M | — | New |
| 14 | VANGUARD FIDUCIARY TRUST CO | 268.0K | $158.9M | — | New |
| 15 | Pacer Advisors, Inc. | 243.5K | $144.4M | — | New |
| 16 | UBS Group AG | 236.7K | $140.4M | — | New |
| 17 | CITIGROUP INC | 235.6K | $139.7M | — | New |
| 18 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 207.3K | $122.9M | — | New |
| 19 | DEUTSCHE BANK AG\ | 198.8K | $117.9M | — | New |
| 20 | Nuveen, LLC | 190.7K | $113.1M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once UTHR's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.